0,1,2,3,4,5,6
Table 6.3.6:  Randomized trials investigating dose escalation for SRT without ADT and without PET-CT,,,,,,
Trial,n,"PCa 
condition","Radiotherapy 
Dose","Follow-up 
(median)",Outcome,Results
"SAKK 09/10 
trial, 2021 
[924]",350,"pT2a-3b
R0 – R1
pN0 or cN0
PSA post-op
undetectable
(< 0.1 ng/mL)
or persistent
(> 0.1 ng/mL  
< 0.4 ng/mL)","64 Gy vs.70 Gy
No ADT allowed
VMAT + IGRT: 
57%
3-D planning: 
43%",6.2 yr.,"Primary 
endpoint:
FFBP","6 yr. FFBP:
62% vs. 61%
OS: no difference
Late side effects:
GI grade 2: 
7.3% vs. 20%
GI grade 3:
4.2% vs. 2.3%
p for > grade 2/3:
0.009"
"Phase-III-Trial 
Qi X, et al., 
2020 [1057]","144
ART: 33%
SRT: 67%","pT2-4
R0-R1
pN0 or cN0
Med. PSA  
pre-RT:  
0.2 ng/mL","66 Gy vs.
72 Gy
All patients 
VMAT + IGRT
No ADT allowed
High risk
(pT3–4, GS: 8–10,
PSA > 20 ng/mL):
whole pelvis RT: 
126 (87.5%)",49 mo.,"Primary 
endpoint:
FFBP","4 yr. FFBP:
75.9% vs. 82.6%
(p > 0.05)
High risk (GS: 8–10):
55.7% vs. 79.7%
p < 0.049)
Late side effects:
GI + GU grade 2
p > 0.05
No grade 3"
